Drug Trial Radar · NCT01191255
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
Last checked: Nov 20, 2026Latest source record: Dec 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
441
Actual
Start
Oct 2010
Primary completion
Jan 2013
Study completion Feb 2013
Sponsor
- Lead sponsor
- Keryx BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
Conditions
- Hyperphosphatemia
- Kidney Failure
Interventions
ferric citrate, ca acetate, sevelamer carbonate, placeboDrug
All intervention doses will be based on serum phosphorus levels and/or drug label requirements
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Serum Phosphorus From Baseline (Week 52) to the End of the Efficacy Assessment Period (EAP; Week 56)Time frame: 4 weeks
Locations
56 sites in 3 countries. Site status is shown where the registry gives one.
Southwest Clinical Research Institute, LLC
Tempe, Arizona
Tower Nephrology Medical Group
Los Angeles, California
Veterans Administration Greater Los Angeles Healthcare System, West Los Angeles
Los Angeles, California
Apex Research of Riverside
Riverside, California
American Institute of Research
Whittier, California
University of Colorado Denver
Aurora, Colorado
Western Nephrology
Westminster, Colorado
PAB Clinical Research
Brandon, Florida
Mayo Clinic
Jacksonville, Florida
ASA Clinical Research, LLC
Jupiter, Florida
Ocala Kidney Group
Ocala, Florida
Pines Clinical Research, Inc.
Pembroke Pines, Florida
Kidney Care Associates, LLC
Augusta, Georgia
Atlanta Nephrology Referral Center
Decatur, Georgia
Circle Medical Management
Chicago, Illinois
Nephrology Specialists, PC
Michigan City, Indiana
LSU Health Sciences Center Section of Nephrology and Hypertension Department of Internal Medicine
New Orleans, Louisiana
Rockville Dialysis Center
Rockville, Maryland
Tufts Medical Center
Boston, Massachusetts
Pioneer Valley Nephrology
Holyoke, Massachusetts
Western New England Renal & Transplant Associates
Springfield, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Michigan Kidney Consultants, PC
Pontiac, Michigan
Nephrology Hypertension Clinic
Southgate, Michigan
Kansas City VA Medical Center
Kansas City, Missouri
Brookdale Physician's Dialysis Associates
Brooklyn, New York
Mountain Kidney and Hypertension Associates, PA
Asheville, North Carolina
Metrolina Nephrology Associates, PA
Charlotte, North Carolina
Duke University Medical Center Division of Nephrology
Durham, North Carolina
Trial Management Associates
Wilmington, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Clinical Research Limited
Canton, Ohio
Division of Nephrology and Hypertension Department of Internal Medicine University of Cincinnati College of Medicine
Cincinnati, Ohio
Cleveland Clinic Foundation Q7-150 Nephrology
Cleveland, Ohio
The Ohio State University Division of Nephrology
Columbus, Ohio
DaVita
Oklahoma City, Oklahoma
University of Pennsylvania Health System
Philadelphia, Pennsylvania
Southeast Renal Research Institute Nephrology Associates
Chattanooga, Tennessee
Nephrology Associates, PC
Nashville, Tennessee
Vanderbilt University Medical Center Clinical Trials Center
Nashville, Tennessee
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.